Strategic Partner,
Earlier this year, OPKO executed a sublicensing deal with IHT to
commercialize OPKO's novel panel of kallikrein biomarkers and associated
algorithm (4Kscore™) for the early detection of prostate cancer in a
laboratory setting in the
IHT, through close cooperation with some of the largest private
hospitals chains in the
"ProstateCheck has been very well received amongst our corporate customers and we have already signed up the first customers," said Troels Jordansen, Chairman of International Health Technology. "The opportunity to identify high grade prostate cancers and focus clinical interventions on these is of great value to men but also to the health care sectors in general. We have very high expectations for this unique service."
"The collaborative efforts with IHT have progressed at an impressive
rate," said
About
IHT specializes in launching new diagnostic technology in the private
sector as part of a clinical service and as a distribution partner. IHT
mainly focuses on the
About
OPKO is a multi-national biopharmaceutical and diagnostics company that seeks to establish industry-leading positions in large and rapidly growing medical markets by leveraging its discovery, development and commercialization expertise and novel and proprietary technologies.
This press release contains "forward-looking statements," as that
term is defined under the Private Securities Litigation Reform Act of
1995 (PSLRA), which statements may be identified by words such as
"expects," "plans," "projects," "will," "may," "anticipates,"
"believes," "should," "intends," "estimates," and other words of similar
meaning, including statements regarding the potential benefits of the
OPKO 4Kscore™, the ability to predict, reduce, or eliminate the need for
biopsies, whether OPKO or IHT will be able to successfully commercialize
the 4Kscore™ or any diagnostic product utilizing the new biomarkers,
whether the product will provide an opportunity to identify high grade
cancers and focus clinical interventions on these, the probability rate
for delaying diagnosis of a high grade cancer, and whether the
biomarkers will offer higher specificity or greater accuracy than
current diagnostics or provide clinicians with a differentiated critical
component in their overall diagnosis of prostate cancer while providing
patients with better and more efficient healthcare, as well as other
non-historical statements about our expectations, beliefs or intentions
regarding our business, technologies and products, financial condition,
strategies or prospects. Many factors could cause our actual activities
or results to differ materially from the activities and results
anticipated in forward-looking statements. These factors include those
described in our filings with the
Source:
News Provided by Acquire Media
